Telomir Pharmaceuticals (TELO) Competitors $4.20 -0.24 (-5.41%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TELO vs. PROK, GLUE, PRTC, TERN, GHRS, MREO, ARCT, ALMS, YMAB, and ZVRAShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include ProKidney (PROK), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Terns Pharmaceuticals (TERN), GH Research (GHRS), Mereo BioPharma Group (MREO), Arcturus Therapeutics (ARCT), Alumis (ALMS), Y-mAbs Therapeutics (YMAB), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. ProKidney Monte Rosa Therapeutics PureTech Health Terns Pharmaceuticals GH Research Mereo BioPharma Group Arcturus Therapeutics Alumis Y-mAbs Therapeutics Zevra Therapeutics ProKidney (NASDAQ:PROK) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Is PROK or TELO more profitable? ProKidney's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Telomir Pharmaceuticals N/A -1,087.92%-806.34% Does the media favor PROK or TELO? In the previous week, ProKidney had 5 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 6 mentions for ProKidney and 1 mentions for Telomir Pharmaceuticals. ProKidney's average media sentiment score of 0.67 beat Telomir Pharmaceuticals' score of 0.00 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, PROK or TELO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-3.00Telomir PharmaceuticalsN/AN/A-$13.07MN/AN/A Do institutionals and insiders believe in PROK or TELO? 51.6% of ProKidney shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate PROK or TELO? ProKidney currently has a consensus target price of $4.50, indicating a potential upside of 172.73%. Given ProKidney's stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor PROK or TELO? ProKidney received 8 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% Telomir PharmaceuticalsN/AN/A SummaryProKidney beats Telomir Pharmaceuticals on 10 of the 11 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.47M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book420.0010.216.946.30Net Income-$13.07M$153.61M$119.12M$225.93M7 Day Performance6.06%-2.00%-1.84%-1.32%1 Month Performance-3.00%-7.47%-3.65%0.60%1 Year PerformanceN/A31.80%31.64%26.23% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir PharmaceuticalsN/A$4.20-5.4%N/AN/A$131.47MN/A0.001News CoveragePROKProKidney2.5946 of 5 stars$1.65-8.3%$4.50+172.7%-6.3%$521.41MN/A0.003News CoverageGLUEMonte Rosa Therapeutics2.9578 of 5 stars$8.36+0.6%$16.00+91.4%+157.2%$510.54MN/A0.0090PRTCPureTech Health2.2392 of 5 stars$21.70+2.1%$45.00+107.4%+0.9%$508.96M$3.33M0.00100Analyst RevisionNews CoveragePositive NewsTERNTerns Pharmaceuticals4.327 of 5 stars$5.60-5.2%$27.25+386.6%+49.3%$501.99M$1M0.0040GHRSGH Research1.3894 of 5 stars$10.95+13.9%$35.67+225.7%+77.2%$499.99MN/A0.0010Analyst ForecastMREOMereo BioPharma Group2.9665 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$489.50M$10M0.0040Analyst RevisionNews CoverageARCTArcturus Therapeutics2.0686 of 5 stars$16.17-10.5%$71.40+341.6%-33.7%$489.20M$169.93M-7.28180ALMSAlumisN/A$9.64-6.9%$26.83+178.4%N/A$488.75MN/A0.00N/AAnalyst RevisionHigh Trading VolumeYMABY-mAbs Therapeutics3.3273 of 5 stars$10.54-2.9%$21.38+102.8%+100.8%$486.41M$84.82M0.00150Analyst ForecastZVRAZevra Therapeutics3.4632 of 5 stars$8.97flat$21.00+134.1%+100.2%$478.78M$27.46M-4.5565Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies ProKidney Alternatives Monte Rosa Therapeutics Alternatives PureTech Health Alternatives Terns Pharmaceuticals Alternatives GH Research Alternatives Mereo BioPharma Group Alternatives Arcturus Therapeutics Alternatives Alumis Alternatives Y-mAbs Therapeutics Alternatives Zevra Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TELO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts